Orum Therapeutics, Inc. Logo

Orum Therapeutics, Inc.

Developing degrader-antibody conjugates for cell-selective protein degradation to treat cancer.

475830 | KO

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
South Korea
Address:
대전광역시 유성구 문지로 281-25, 대전광역시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Orum Therapeutics, Inc. is a clinical-stage biotechnology company pioneering a novel class of therapeutics using its proprietary TPD²® platform for cell-selective degradation. This technology combines the power of targeted protein degraders with the precision of antibodies to create degrader-antibody conjugates (DACs). The company's approach is designed to improve upon the efficacy, safety, and half-life of conventional protein degraders. Orum is focused on building a portfolio of highly differentiated products to treat diseases with high unmet medical needs, including cancer, by expanding the landscape of druggable targets.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-29 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 348.3 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.1 MB
2025-08-08 00:00
Major Shareholding Notification
[기재정정]주식등의대량보유상황보고서(일반)
Korean 382.4 KB
2025-08-08 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 339.8 KB
2025-08-01 00:00
Post-Annual General Meeting Information
임시주주총회결과
Korean 10.7 KB
2025-08-01 00:00
Remuneration Information
주식매수선택권부여에관한신고
Korean 21.5 KB
2025-07-25 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 368.6 KB
2025-07-17 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 77.7 KB
2025-07-10 00:00
Pre-Annual General Meeting Information
[기재정정]주주총회소집결의
Korean 16.8 KB
2025-06-25 00:00
Pre-Annual General Meeting Information
주주총회소집결의
Korean 10.7 KB
2025-06-25 00:00
Pre-Annual General Meeting Information
주주명부폐쇄기간또는기준일설정
Korean 4.2 KB
2025-06-04 00:00
Major Shareholding Notification
[기재정정]주식등의대량보유상황보고서(일반)
Korean 372.2 KB
2025-06-04 00:00
Major Shareholding Notification
[기재정정]주식등의대량보유상황보고서(일반)
Korean 360.6 KB
2025-05-26 00:00
Report Publication Announcement
기업설명회(IR)개최
Korean 6.7 KB
2025-05-22 00:00
Report Publication Announcement
기업설명회(IR)개최
Korean 6.7 KB

Automate Your Workflow. Get a real-time feed of all Orum Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Orum Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Fine Foods & Pharmaceuticals Ntm Logo
Contract development & manufacturing of oral solids for pharma, nutraceutical & cosmetic sectors.
Italy FF
Formycon AG Logo
Develops cost-effective biosimilars for ophthalmology, immunology, and other chronic diseases.
Germany FYB
Friulchem Logo
CDMO for animal health, providing vet pharma & supplement solutions for pets and livestock.
Italy FCM
Fuji Pharma Co.,Ltd. Logo
Specializes in hormone medicines for ob/gyn, injectables, and contract manufacturing.
Japan 4554
Fuso Pharmaceutical Industries,Ltd. Logo
Manufactures essential pharmaceuticals like dialysis drugs, infusions, and injections for healthcare.
Japan 4538
FutureChem Co., Ltd. Logo
Develops radiopharmaceuticals & diagnostic agents for cancer, Alzheimer's, and Parkinson's disease.
South Korea 220100
Future Medicine  Co., Ltd. Logo
Clinical-stage biopharma developing novel synthetic drugs for inflammation, fibrosis, and oncology.
South Korea 341170
Develops long-acting injectable therapies for chronic diseases and cancer.
South Korea 456160
Gabather AB Logo
Developing novel GABAA receptor drugs for neuropsychiatric disorders.
Sweden GABA
Galapagos NV Logo
Biotech firm developing novel CAR-T cell therapies for oncology via a rapid delivery platform.
Belgium GLPG

Talk to a Data Expert

Have a question? We'll get back to you promptly.